TrialRheumatology (Oxford, England)2025

A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's.

Göran Tornling et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.